Health care stocks were easing late Monday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each down 0.1%.
The iShares Biotechnology ETF (IBB) rose 0.4%.
In corporate news, Revolution Medicines (RVMD) shares tumbled past 9% after the company presented preliminary data for its RMC-6236 and RMC-6291 drug candidates in people with several forms of cancer.
Grifols (GRFS) shareholder Mason Capital Management's co-founder Kenneth Garschina is seeking a Grifols board revamp and a seat at the table, replacing Tomas Daga, Garschina told Bloomberg in an interview. Grifols shares rose 1.5%.
PTC Therapeutics (PTCT) signed a licensing deal with Novartis (NVS) unit Novartis Pharmaceuticals worth up to $2.9 billion for PTC518, its candidate treatment for Huntington's disease. PTC shares jumped 19% and Novartis was down 0.9%.
Senti Biosciences (SNTI) shares soared 377%. The company said Monday that two of three acute myeloid leukemia patients treated with its Senti-202 investigational cell therapy for blood cancers achieved complete remission in a phase 1 trial.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。